Does Canada have Ozempic savings cards?

Yes. Novo Nordisk Canada announced extra Ozempic savings for eligible Canadians without public or private coverage effective May 29, 2026. The company says cards can be used at local pharmacies across Canada, excluding Quebec, and through select partners. Eligibility and final price must be confirmed before filling.

How much does Ozempic cost in Canada?

Recent Canadian retail trackers and news reports place Ozempic commonly around CAD $253 to $450 per month, depending on province, pharmacy, dose, and whether a savings card or insurance applies. Prices change often, so verify the exact DIN and pharmacy quote.

Is Ozempic approved for weight loss in Canada?

Ozempic is approved in Canada for adults with type 2 diabetes and specified cardiovascular and kidney-risk indications. Wegovy is the semaglutide brand used for chronic weight management. Some clinicians may prescribe Ozempic off-label, but coverage is often harder for weight-loss use.

Are generic versions of Ozempic available in Canada?

Health Canada approved the first generic semaglutide injection in April 2026 and a second in May 2026 for adult type 2 diabetes. Approval does not always mean immediate pharmacy availability, and pricing can vary as supply ramps up.

Back to Blog

Pricing & AccessMay 29, 202610 min read

Ozempic, Wegovy, and Mounjaro Savings in Canada: What to Check Before You Pay

Canadian GLP-1 savings are real, but they are not one-size-fits-all. Before paying for Ozempic, Wegovy, Mounjaro, or Zepbound, check the exact indication, DIN, province, private coverage, pharmacy price, and manufacturer savings program.

The Short Answer

If you are in Canada, the cheapest path depends on why the drug is prescribed. Ozempic and Mounjaro are often covered, if covered at all, through type 2 diabetes criteria. Wegovy and Zepbound are the more direct obesity-treatment brands, but public weight-loss coverage is still limited and many patients pay cash.

Best first move

Do not start with a coupon site. Start with your prescription details: drug name, dose, DIN, indication, province, and whether your prescriber wrote diabetes, chronic weight management, or another approved use. Then compare the pharmacy cash price against manufacturer support and private coverage.

This page is Canada-specific. If you are comparing US telehealth cash-pay programs, use our broader guide to GLP-1 access without insurance instead.

Canadian GLP-1 Cash Price Ranges to Sanity-Check

Canadian prices are usually lower than US list prices, but they still vary by pharmacy, province, dose, and product. GLP1Prices.ca reported the following self-pay ranges in March 2026, and Canadian news reports in May 2026 cited Ozempic or Wegovy commonly around CAD $300 to $400 or more per month.

Drug	Active ingredient	Recent cash range	Key caveat
Ozempic	semaglutide	$253-$308 per month	Novo Nordisk Canada announced extra savings for eligible uninsured Canadians starting May 29, 2026. Excludes Quebec.
Wegovy	semaglutide 2.4 mg	$400-$570 per month	Approved for chronic weight management in Canada. Provincial obesity coverage is still limited.
Mounjaro	tirzepatide	$301-$502 per month	Approved for type 2 diabetes in Canada. Weight-loss use may be off-label depending on indication and province.
Zepbound	tirzepatide	$315-$567 per month	Lilly's myzepbound program may lower cash-pay or insured out-of-pocket costs for eligible Canadian residents.

Treat these as quote-checking ranges, not guaranteed prices. Your pharmacy quote, dispensing fee, dose, and card eligibility determine the actual amount you pay.

Savings Programs Worth Checking

Novo Nordisk Care and Ozempic savings

Novo Nordisk Canada announced extra Ozempic savings for eligible Canadians without public or private coverage effective May 29, 2026. The release says cards work at local pharmacies across Canada, excluding Quebec, and through Novo Nordisk Care Rx operated by Rexall and select partners.

innoviCares

innoviCares can help reduce the brand-to-generic cost difference for participating medicines. It is useful when a brand product is preferred, but it does not override every provincial, Quebec, or plan limitation.

mymounjaro and myzepbound

Lilly Canada programs may reduce eligible out-of-pocket costs and help with reimbursement navigation. The exact savings depend on drug, indication, insurance, and whether you apply before purchase.

Private insurance and employer benefits

Commercial benefits may cover GLP-1s for type 2 diabetes while excluding anti-obesity medications. Ask for a written formulary decision by DIN, not a generic answer about GLP-1 coverage.

The important caveat: a savings card is not the same thing as insurance coverage. It can reduce your share, but it may still leave you paying hundreds per month if your base pharmacy price is high or the program cap is low.

Coverage: Diabetes vs Weight Loss Is the Big Split

The Canadian Medical Association notes that Wegovy is approved for chronic weight management, while Ozempic is not approved for weight loss in Canada. Ozempic is approved for type 2 diabetes, with cardiovascular and kidney-risk indications in specific adult patients. Mounjaro is positioned in Canada as tirzepatide for type 2 diabetes discussions. That distinction matters because many public and private plans cover diabetes treatment more readily than obesity treatment.

What to ask your insurer

Is this exact DIN covered for my diagnosis?
Is prior authorization required?
Does the plan exclude anti-obesity medications?
Are Ozempic, Wegovy, Mounjaro, and Zepbound handled differently?
Will the savings card coordinate with my plan at the pharmacy?

If the answer is vague, ask the pharmacy to run a test claim. A phone rep saying a drug is “covered” can still mean your claim fails because the diagnosis, DIN, dose, or prior authorization file does not match.

Generic Semaglutide Changes the Savings Math

Health Canada approved the first generic semaglutide injection from Dr. Reddy's Laboratories in April 2026, then approved a second generic semaglutide from Apotex in May 2026. Global News reported that Canada became the first G7 country to authorize generic semaglutide, with seven additional submissions under review.

That sounds like instant savings, but the pharmacy reality can be slower. Approval does not guarantee that your local pharmacy has stock, that your insurer has loaded the product, or that the lower price is available for your specific indication. Health Canada's approvals cited adult type 2 diabetes use, not a blanket weight-loss approval.

The practical move: ask your prescriber and pharmacist whether a generic semaglutide DIN is appropriate for your diagnosis, then compare the generic quote with Ozempic savings-card pricing. Sometimes brand support narrows the gap.

Clinical Context: Why People Still Compare These Drugs Despite the Cost

The savings search exists because these medications can produce clinically meaningful weight loss when used for appropriate patients under medical supervision. In the STEP 1 trial, John P. H. Wilding and colleagues reported in the New England Journal of Medicine in 2021 that semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo in 1,961 adults without diabetes.

For tirzepatide, Ania M. Jastreboff and the SURMOUNT-1 investigators reported in the New England Journal of Medicine in 2022 that participants lost 16.0% to 22.5% of body weight at 72 weeks on 5 mg, 10 mg, or 15 mg tirzepatide, compared with 2.4% on placebo using the efficacy estimand. Lilly's summary also reported 89% to 96% of participants achieved at least 5% weight loss, versus 28% with placebo.

Those trial results do not mean every patient should pay cash. They do mean that if you and your clinician decide a GLP-1 is appropriate, it is worth checking every legitimate Canadian savings path before assuming the first quote is the best quote.

Buyer Checklist Before You Pay

Confirm the indication

Ozempic and Mounjaro coverage is often diabetes-focused. Wegovy and Zepbound are the obesity-brand conversations.

Ask your insurer for the DIN decision

Canadian benefit decisions are often tied to the exact drug identification number, dose, and indication.

Compare pharmacy prices before using a card

Canadian cash prices can vary by $50 or more per month between pharmacies.

Check manufacturer and innoviCares programs

Savings cards can reduce copays, but eligibility, Quebec availability, and insurance rules differ.

Recheck generic semaglutide timing

Health Canada approved the first generic semaglutide in April 2026 and a second in May 2026, but pharmacy availability and pricing can lag approval.

Avoid this shortcut

Do not buy products advertised as research semaglutide, research tirzepatide, or no-prescription Ozempic. Canadian savings programs require legitimate prescriptions and pharmacy dispensing. If a seller skips that, the risk is not worth the discount.

Bottom Line

For Canadian GLP-1 shoppers, savings come from stacking the boring checks: exact drug, exact DIN, indication, plan rules, pharmacy quote, manufacturer support, and generic availability. Ozempic savings improved in late May 2026 for eligible uninsured Canadians, and generic semaglutide approvals may lower costs over time. But coverage for weight-loss use remains uneven.

If you are paying cash today, call at least two pharmacies, check the manufacturer program before filling, and ask your insurer or pharmacist to verify the DIN in writing. The difference can be hundreds of dollars over a few months.

Sources

Related Guides

Provider Guide

Telehealth Provider Comparison →

Cash-Pay Guide

GLP-1 Without Insurance →

Safety Guide

Compounded vs Brand GLP-1s →

Pricing & Access11 min read

How to Get GLP-1 Medications Without Insurance in 2026

Pricing & Access10 min read

How to Save Money on Semaglutide and Tirzepatide in 2026

💰

PRICE WATCH

Track GLP-1 access and pricing

Get evidence-based GLP-1 pricing updates, safety notes, and provider comparisons in your inbox.